RBS Australia 21/09/2009 1 Buy $37.50 9.1%
The broker notes 4th quarter CMS reimbursements in the US are showing price declines in some plasma products but rather than adjust its forecasts it suggests the latest outcomes support its medium-term price assumptions for the company.
As a result the broker retains its Buy rating and $37.50 price target, supported by its view there is upside potential from any possible global pharma bid for the company.
latest rating, page-2
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.48 |
Change
2.815(0.95%) |
Mkt cap ! $144.7B | |||
| Open | High | Low | Value | Volume |
| $300.00 | $300.67 | $299.34 | $64.10M | 213.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71 | $300.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.48 | 89 | 6 |
View Market Depth
| Last trade - 12.53pm 11/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |